Paper · 23964934
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Motzer RJ and 24 others. N Engl J Med, 2013. Cited by 1,522 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. Papers, record 23964934. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23964934
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Angiogenesis Inhibitors | Major topic |
| Carcinoma, Renal Cell | Major topic |
| Indoles | Major topic |
| Kidney Neoplasms | Major topic |
| Pyrimidines | Major topic |
| Pyrroles | Major topic |
| Sulfonamides | Major topic |
| Adult | |
| Disease-Free Survival | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Indazoles | |
| Kaplan-Meier Estimate | |
| Male | |
| Quality of Life | |
| Sunitinib |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30CA008748 | NIH |
Source NIH RePORTER
Trials5
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00720941 | Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT02535351 | Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery | Background | ClinicalTrials.gov | |
| NCT03463681 | A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma | Results | ClinicalTrials.gov | |
| NCT04462445 | Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb | Results | ClinicalTrials.gov | |
| NCT07172386 | Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC | Background | ClinicalTrials.gov |
Comments and corrections8
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 24,018,564 | Kidney cancer: Comparing first-line treatments for mRCC. | https://conductscience.org/library/papers/24018564 | PubMed |
| Comment in | 24,224,635 | Pazopanib versus sunitinib in renal cancer. | https://conductscience.org/library/papers/24224635 | PubMed |
| Comment in | 24,224,636 | Pazopanib versus sunitinib in renal cancer. | https://conductscience.org/library/papers/24224636 | PubMed |
| Comment in | 24,224,637 | Pazopanib versus sunitinib in renal cancer. | https://conductscience.org/library/papers/24224637 | PubMed |
| Comment in | 24,224,638 | Pazopanib versus sunitinib in renal cancer. | https://conductscience.org/library/papers/24224638 | PubMed |
| Comment in | 24,253,418 | First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profile. | https://conductscience.org/library/papers/24253418 | PubMed |
| Comment in | 24,484,761 | Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. | https://conductscience.org/library/papers/24484761 | PubMed |
| Comment in | 24,646,500 | Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. | https://conductscience.org/library/papers/24646500 | PubMed |
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by889
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,522 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,942,141 | VEGF Signaling and Targeted Therapies in Cancer: Molecular Mechanisms, Clinical Applications, Resistance, and Cardiorenal Toxicities. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42942141 | PubMed |
| 42,914,499 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. | ESMO Open | 2026 | https://conductscience.org/library/papers/42914499 | PubMed |
| 42,885,310 | Navigating the landscape of targeted therapies for renal cell carcinoma in the era of precision medicine (Review). | Mol Med Rep | 2026 | https://conductscience.org/library/papers/42885310 | PubMed |
| 42,795,917 | Comparative Evaluation of the Effectiveness of Nivolumab Versus Axitinib in the Second-Line Treatment of Patients with Metastatic Renal Cell Carcinoma: A Two-Center Experience. | J Clin Med | 2026 | https://conductscience.org/library/papers/42795917 | PubMed |
| 42,789,725 | Converting lysosomes into photothermal organelles enables nanoparticle-free tumor ablation via intracellular vapor bubbles. | Sci Adv | 2026 | https://conductscience.org/library/papers/42789725 | PubMed |
| 42,745,780 | Reduced-Dose Pazopanib as First-Line Therapy in Metastatic Renal Cell Carcinoma: Real-World Outcomes and Subsequent Treatment Patterns from a Resource-Constrained Setting in South India. | J Kidney Cancer VHL | 2026 | https://conductscience.org/library/papers/42745780 | PubMed |
| 42,739,731 | Renal Cell Carcinoma in the Geriatric Population: Toward a Frailty-Adapted Therapeutic Paradigm. | J Clin Med | 2026 | https://conductscience.org/library/papers/42739731 | PubMed |
| 42,738,252 | Association Between Body Mass Index and Treatment Toxicity in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42738252 | PubMed |
| 42,680,845 | Renal cell carcinoma: molecular understanding and therapeutic development. | Cell Death Differ | 2026 | https://conductscience.org/library/papers/42680845 | PubMed |
| 42,577,666 | First-line immune checkpoint inhibitor plus anti-angiogenic therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42577666 | PubMed |
1 to 10 of 889
See all 889 cited byGenes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs3
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| CABOZANTINIB | CHEMBL2105717 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL2105717 | ChEMBL |
| PAZOPANIB | CHEMBL477772 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL477772 | ChEMBL |
| SUNITINIB | CHEMBL535 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL535 | ChEMBL |
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23964934
GET https://conductscience.org/api/papers/v1/23964934/authors?page=2